Sophiris Bio Inc. (NASDAQ:SPHS) shares were up 8.9% on Thursday . The stock traded as high as $3.78 and last traded at $3.68, with a volume of 3,936,980 shares traded. The stock had previously closed at $3.38.

Several research analysts recently weighed in on SPHS shares. Maxim Group restated a “buy” rating and set a $4.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th. Echelon Wealth Partners restated a “buy” rating and set a $5.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th.

The firm has a 50-day moving average of $4.43 and a 200-day moving average of $2.28. The company’s market capitalization is $73.27 million.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.